Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as REC-4539
EXS74539 · 1 trial · 12 indications
| Arm | Type | Description |
|---|---|---|
| EXS74539 | EXPERIMENTAL | EXS74539 |
| Name | Type | Description |
|---|---|---|
| EXS74539 | DRUG | Oral administration |
Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Histologically confirmed diagnosis of the following solid tumors: * SCLC * High grade neuroendocrine or small cell carcinomas of non-lung origin * Non-small cell lung cancer \[NSCLC\] * Prostat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
EXS74539 is an investigational small molecule drug being developed by Recursion Pharmaceuticals, Inc. for the treatment of select solid tumors. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in a dose-determining trial in adults with advanced solid tumors.
EXS74539 is being studied for the treatment of select solid tumors, including small cell lung cancer, high grade neuroendocrine cancer, non-small cell lung cancer, prostate cancer, ovarian cancer, renal carcinoma, head and neck squamous cell carcinoma, hepatic cancer, gastric cancer, and triple-negative breast cancer. It is investigational and not yet approved for any indication.
EXS74539 targets LSD1, also known as lysine-specific demethylase 1, which is an enzyme. By inhibiting this enzyme, the drug is designed to act on biological pathways relevant to tumor growth. The Phase 1 trial enrolls patients with biomarker-selected solid tumors, meaning participants are chosen based on specific tumor characteristics.
EXS74539 is being developed by Recursion Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker symbol RXRX. The company is running the clinical program for this small molecule oncology candidate, which is also referred to as REC-4539 in its trial documentation.
EXS74539 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 study is a dose-determining trial designed to evaluate the drug in participants with select solid tumors, and it is currently recruiting.
EXS74539 is being evaluated in one clinical trial, NCT07517198, titled Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors. The Phase 1 trial is currently recruiting and plans to enroll approximately 40 participants aged 18 years and older in the United States. It is an uncontrolled, non-randomized study.
Yes, EXS74539 is also known as REC-4539. The two names refer to the same investigational small molecule. The Phase 1 trial is listed under both names, so readers searching for REC-4539 will find the same drug and the same clinical program being developed by Recursion Pharmaceuticals, Inc.